Research Paper Volume 13, Issue 17 pp 21102—21121

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK


Figure 2. BTK expression in the MCL cell lines and cell viability treated with BGB-3111. (A) The BTK expression in the five MCL cell lines. (B) Cell viability in the Jeko-1, Rec-1, and Z138 treated with BGB-3111 for 48 or 72 h. Results are the mean ± SD of three independent experiments.